The author looks at three cutting-edge products that use RF energy. Unlike the mono- and bipolar instruments in use today, these new devices cool tissue to create more powerful electrosurgical tools.
Tebipenem HBr cUTI trial ends early after meeting efficacy goals
May 28th 2025GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.
Read More